Cardiovascular effects after hematopoietic stem cell transplantation

Česká verzia

Authors: Ľ. Roziaková; B. Mladosievičová
Authors place of work: Oddelenie klinickej patofyziológie Ústavu patologickej fyziológie Lekárskej fakulty UK Bratislava, Slovenská republika, prednosta doc. MU Dr. Marián Bernadič, CSc., mim. prof.
Published in the journal: Vnitř Lék 2010; 56(3): 233-239
Category: Reviews

Summary

Increasing numbers of patients now survive long‑term following hematopoietic stem cell transplantation (HSCT). Hematopoietic stem cell transplantation can induce damage of various organs and tissues – from minimal potentially progressive subclinical changes to life‑ threatening conditions. These potential complications and effects include endocrine, respiratory, skeletal, neurological and other complications, as well as cardiotoxicity and secondary malignancies. Cardiovascular effects belong to life‑ threatening. There is a possibility of decreasing these effects – by their prevention, earlier diagnosis and treatment. It is necessary for the patient to receive lifelong care including cardiology follow‑up after such intensive oncologic treatment.

Key words:
hematopoietic stem cell transplantation – cardiovascular effects

Zdroje

1. Bhatia S, Francisco L, Carter A et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long‑term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110: 3784– 3792.

2. Bhatia S, Robison LL, Francisco L et al. Late mortality in survivors of autologous hematopoietic‑ cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005; 105: 4215– 4222.

3. Mladosievičová B, Čáp J, Kaiserová E et al. Neskoré následky po cytostatickej liečbe v detstve. In: Mladosievičová B, Kaiserová E, Foltinová A et al (eds). Možné neskoré následky protinádorovej liečby v detstve. Bratislava: Slovak Academic Press 2007: 29– 55.

4. Faraci M, Békássy AN, De Fazio V et al. EBMT Paediatric and Late Effects Working Parties. Non‑ endocrine late complications in children after allogeneic haematopoietic SCT. Bone Marrow Transplant 2008; 41 (Suppl 2): S49– S57.

5. Murdych T, Weisdorf DJ. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977– 1997. Bone Marrow Transplantation 2001; 28: 283– 287.

6. Armand P, Kim HT, Cutler CS et al. A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 28– 35.

7. Sorror M. Impacts of pretransplant comorbidities on allogeneic hematopoietic cell transplantation (HCT) outcomes. Biol Blood Marrow Transplant 2009; 15 (Suppl 1): 149– 153.

8. Kubešová H, Elbl L. Problematika kardiálních komplikací v souvislosti s transplantací krvetvorných bunek. In: Elbl L, Hrstková H, Chaloupka V et al (eds). Poškození srdce protinádorovou léčbou. Praha: Grada 2002: 118– 131.

9. Morandi P, Ruffini PA, Benvenuto GM et al. Cardiac toxicity of high‑dose chemotherapy. Bone Marrow Transplant 2005; 35: 323– 334.

10. Milone G, Mercurio S, Strano A et al. Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non‑mononuclear cells in the infused suspension and patient age. Cytotherapy 2007; 9: 348– 355.

11. Windrum P, Morris TC, Drake MB et al. Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres. Bone Marrow Transplant 2005; 36: 601– 603.

12. Kuruvilla J, Forrest DL, Lavoie JC et al. Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 34: 969– 973.

13. Tichelli A, Bhatia S, Socié G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol 2008; 142: 11– 26.

14. Rackley C, Schultz KR, Goldman FD et al. Cardiac manifestations of graft versus‑ host disease. Biol Blood Marrow Transplant 2005; 11: 773– 780.

15. Woywodt A, Haubitz M, Buchholz S et al. Counting the cost: markers of endothelial damage in hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 34: 1015– 1023.

16. Biedermann BC, Tsakiris DA, Gregor M et al. Combining altered levels of effector transcripts in circulating T cells with a marker of endothelial injury is specific for active graft‑ versus‑ host disease. Bone Marrow Transplant 2003; 32: 1077– 1084.

17. Woywodt A, Scheer J, Hambach L et al. Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. Blood 2004; 103: 3603– 3605.

18. Tichelli A, Gratwohl A. Vascular endothelium as ‘novel’ target of graft‑ versus‑ host disease. Best Pract Res Clin Haematol 2008; 21: 139– 148.

19. Uderzo C, Pillon M, Corti P et al. Impact of cumulative anthracycline dose, preparative regimen and chronic graft‑ versus‑ host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties. Bone Marrow Transplant 2007; 39: 667– 675.

20. Tichelli A, Passweg J, Wójcik D et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2008; 93: 1203– 1210.

21. Sakata‑ Yanagimoto MS, Kanda Y, Nakagawa M et al. Predictors for severe cardiac complications after hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33: 1043– 1047.

22. Tichelli A, Bucher C, Rovó A et al. Premature cardiovascular disease after allogeneic hematopoietic stem cell transplantation. Blood 2007; 110: 3463– 3471.

23. Basavaraju SR, Easterly CE. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med Phys 2002; 29: 2391– 2403.

24. Biedermann BC, Sahner S, Gregor M et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002; 359: 2078– 2083.

25. Murata H, Janin A, Leboeuf C et al. Donor‑ derived cells and human graft‑ versus‑ host disease of the skin. Blood 2007; 109: 2663– 2665.

26. Gatt ME, Liebster D, Leibowitz D et al. Acute myocardial infarction after bone marrow transplantation: an unsuspected late complication. Ann Hematol 2003; 82: 136– 138.

27. Ghobrial IM, Bunch TJ, Caplice NM et al. Fatal coronary artery disease after unrelated donor bone marrow transplantation. Mayo Clin Proc 2004; 79: 403– 406.

28. Coplin WM, Cochran MS, Levine SR et al. Stroke after bone marrow transplantation: frequency, aetiology and outcome. Brain 2001; 124: 1043– 1051.

29. Nuver J, Smit AJ, Postma A et al. The metabolic syndrome in long‑term cancer survivors, an important target for secondary preventive measures. Cancer Treat Rev 2002; 28: 195– 214.

30. Couriel DR, Saliba R, Escalón MP et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft‑ versus‑ host disease. Br J Haematol 2005; 130: 409– 417.

31. Taskinen M, Saarinen‑ Pinkala UM, Hovi L et al. Impaired glucose tolerance and dyslipidaemia as late effects after bone‑ marrow transplantation in childhood. Lancet 2000; 356: 993– 997.

32. Shalitin S, Phillip M, Stein J et al. Endocrine dysfunction and parameters of the metabolic syndrome after bone marrow transplantation during childhood and adolescence. Bone Marrow Transplant 2006; 37: 1109– 1117.

33. Higgins K, Noon C, Davies M et al. Features of the metabolic syndrome present in survivors of bone marrow transplantation in adulthood. Bone Marrow Transplant 2004; 36: 279– 280.

34. Gurney JG, Ness KK, Sibley SD et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer 2006; 107: 1303– 1312.

35. Neville KA, Cohn RJ, Steinbeck KS et al. Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: prevalence and risk factors. J Clin Endocrinol Metab 2006; 91: 4401– 4407.

36. Baker KS, Ness KK, Steinberger J et al. Diabetes, hypertension, and cardiovascular events in survivors of HCT: a report from the bone marrow transplantation survivor study. Blood 2007; 109: 1765– 1772.

37. Hoffmeister PA, Storer BE, Sanders JE. Diabetes mellitus in long‑term survivors of pediatric hematopoietic cell transplantation. J Pediatr Hematol Oncol 2004; 26: 81– 90.

38. Urbanová D, Mladosievicova B. Cardiotoxicity of antracycline treatment in the light of new biochemical diagnostic options. Vnitř Lék 2007; 53: 669– 677.

39. Elbl L, Vásová I, Navrátil M et al. Comparison of plasmatic levels of B‑ natriuretic peptide with echocardiographic indicators of left ventricle function after doxorubicin therapy. Vnitř Lék 2006; 52: 563– 570.

40. De Lemos JA, Morrow DA. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. Rev Cardiovasc Med 2003; 4 (Suppl 4): S37– S46.

41. Horacek JM, Pudil R, Tichy M et al. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia. Exp Oncol 2007; 29: 343– 347.

42. Masuko M, Ito M, Kurasaki T et al. Plasma brain natriuretic peptide during myeloablative stem cell transplantation. Intern Med 2007; 46: 551– 555.

43. Elbl L, Hrstkova H, Chaloupka V et al. Diagnostic possibilities of late cardiotoxic sequelae of chemotherapy with anthracyclines. Vnitř Lék 2002; 48: 981– 988.

44. Rizzo JD, Wingard JR, Tichelli A et al. Recommended screening and preventive practices for long‑term survivors after hematopoietic cell transplantation joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006; 12: 138– 151.

45. Carver JR, Shapiro CL, Ng A et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007; 25, 3991– 4008.

46. Coghlan JG, Handler CE, Kottaridis PD. Cardiac assessment of patients for haematopoietic stem cell transplantation. Best Pract Res Clin Haematol 2007; 20: 247– 263.

47. Sakiyama M, Kami M, Hori A et al. Regimen‑related toxicity following reduced‑ intensity stem‑ cell transplantation (RIST): comparison between Seattle criteria and National Cancer Center Common Toxicity Criteria (NCI‑ CTC) version 2.0. Bone Marrow Transplant 2004; 34: 787– 794.

48. Wang XS. Pathophysiology of cancer‑related fatigue. Clin J Oncol Nurs 2008; 12 (Suppl 5): 11– 20.

49. National Comprehensive Cancer Network CRF Panel. Practice Guidelines in Oncology – v.2.2005: Cancer‑ RelatedFatigue. Available from: http:/ / www.nccn.org/ professionals/ physician_gls/ PDF/ fatigue.pdf. 2005.

50. Barsevick AM, Newhall T, Brown S. Management of cancer‑related fatigue. Clin J Oncol Nurs 2008; 12 (Suppl 5): 21– 25.

51. National Cancer Center Common Toxicity Criteria (NCI-CTC), version 4.0, published 2009. Available from: http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/ctc.htm#ctc_40.